Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domvanalimab and Zimberelimab in Recurrent Glioblastoma
NCT04656535Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- Apr 2021
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of domvanalimab and zimberelimab in glioblastoma (GBM) (5 cohorts), sponsored by Yale University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 2 years. Started Apr 2021; status: active, not recruiting.
02
Drugs
domvanalimabzimberelimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04656535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656535.